Evommune, Inc. EVMN

US Biotechnology

$8.01 ▲ +4.71% (+$0.36)

⬆️ Above Yest. High

Open $7.48

Prev Close $7.65

Day Range $7.41 – $8.09

52W Range $4.94 – $33.20

Market Cap $277.63M

Beta 0.58

EPS (TTM) $-3.83

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NEW YORK STOCK EXCHANGE, INC.
Currency	USD
IPO Date	2025-11-06
Shares Out.	36,290,000
Website	evommune.com/ ↗
Phone	13025310855
Employees	48
Revenue	$0
Gross Profit	$0
Net Income	-$32.2M
Free Cash Flow	-$91.1M
Total Assets	$301.9M
Total Liabilities	$24.4M
Equity	$277.6M

About Evommune, Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Evommune, Inc. is a publicly traded company under the ticker symbol EVMN on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.